Ibalizumab: First Global Approval.

Link to article at PubMed

Related Articles

Ibalizumab: First Global Approval.

Drugs. 2018 Apr 19;:

Authors: Markham A

TaiMed Biologics is developing ibalizumab (Trogarzo™, ibalizumab-uiyk)-a humanised IgG4 monoclonal antibody-as a treatment for HIV-1 infection. Ibalizumab blocks HIV entry into CD4 cells while preserving normal immunological function and is the first CD4-directed post-attachment HIV-1 inhibitor and the first humanised monoclonal antibody for the treatment of HIV/AIDS. This article summarizes the milestones in the development of ibalizumab leading to this first approval in HIV-1 treatment.

PMID: 29675744 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published. Required fields are marked *